News
Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...
GlobalData on MSN7h
Prasad’s shock FDA return reignites regulatory uncertaintyVinay Prasad resumes leadership at the FDA’s CBER two weeks after he resigned amid cell and gene therapy controversy.
BACK TO CBER — Dr. Vinay Prasad has returned to the FDA’s Center for Biologics Evaluation and Research, leaving industry and ...
Vor Bio appoints Dallan Murray as chief commercial officer, leveraging his extensive experience to drive commercialization ...
The shares of biotech companies fell after news that ousted regulator Vinay Prasad is set to go back to the US Food and Drug Administration. Prasad had previously overruled his own scientific review ...
WASHINGTON, DC – Dr. Vinay Prasad has been reinstated to a senior position at the Food and Drug Administration, according to ...
Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the U.S. Food and Drug ...
With a strong launch underway for a bladder cancer gene therapy, Ferring Pharmaceuticals is finding the kind of commercial ...
Health and Me on MSN17h
FDA Vaccination Chief Vinay Prasad Returns To Job Within Days After Quitting Under Pressure, Who Is He?Dr. Vinay Prasad, ousted as FDA’s top vaccine and gene therapy regulator amid political backlash, has been reinstated. Known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback